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Pathogenic NR2F1 variants cause a rare autosomal dominant neurodevelopmental disorder referred to as the Bosch–Boonstra–
Schaaf Optic Atrophy Syndrome. Although visual loss is a prominent feature seen in affected individuals, the molecular and cellular
mechanisms contributing to visual impairment are still poorly characterized. We conducted a deep phenotyping study on a cohort
of 22 individuals carrying pathogenic NR2F1 variants to document the neurodevelopmental and ophthalmological manifestations,
in particular the structural and functional changes within the retina and the optic nerve, which have not been detailed previously.
The visual impairment became apparent in early childhood with small and/or tilted hypoplastic optic nerves observed in 10 cases.
High-resolution optical coherence tomography imaging confirmed significant loss of retinal ganglion cells with thinning of the gan-
glion cell layer, consistent with electrophysiological evidence of retinal ganglion cells dysfunction. Interestingly, for those individu-
als with available longitudinal ophthalmological data, there was no significant deterioration in visual function during the period of
follow-up. Diffusion tensor imaging tractography studies showed defective connections and disorganization of the extracortical vis-
ual pathways. To further investigate how pathogenic NR2F1 variants impact on retinal and optic nerve development, we took ad-
vantage of an Nr2f1 mutant mouse disease model. Abnormal retinogenesis in early stages of development was observed in Nr2f1
mutant mice with decreased retinal ganglion cell density and disruption of retinal ganglion cell axonal guidance from the neural
retina into the optic stalk, accounting for the development of optic nerve hypoplasia. The mutant mice showed significantly
reduced visual acuity based on electrophysiological parameters with marked conduction delay and decreased amplitude of the
recordings in the superficial layers of the visual cortex. The clinical observations in our study cohort, supported by the mouse data,
suggest an early neurodevelopmental origin for the retinal and optic nerve head defects caused by NR2F1 pathogenic variants,
resulting in congenital vision loss that seems to be non-progressive. We propose NR2F1 as a major gene that orchestrates early ret-
inal and optic nerve head development, playing a key role in the maturation of the visual system.
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32 Department of Ophthalmology, Hospital Sant Joan de Déu, Barcelona, Spain
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Introduction
Inherited optic neuropathies are an important cause of
visual impairment in young children with an estimated
prevalence of 1 in 10 000.1 Although genetically heteroge-
neous with both nuclear and mitochondrial genes being
implicated, the pathological hallmark is the marked vul-
nerability of retinal ganglion cells (RGCs) leading to optic
nerve degeneration and irreversible visual loss.2 In auto-
somal dominant or recessive optic atrophy caused by
pathogenic OPA1 (OMIM 605290) and WFS1 (OMIM
606201) variants, progressive RGC loss starts in early
childhood and most patients are registered legally blind
by the fifth decade of life.3 High-resolution optical coher-
ence tomography (OCT) imaging has made it possible to
visualize and monitor the loss of RGCs, and in most
inherited optic neuropathies, there is early loss of RGCs
within the papillomacular bundle that becomes more gen-
eralized as the disease progresses.1,4 Optic nerve hypopla-
sia (ONH) is a non-progressive congenital disease
characterized by underdevelopment of the optic nerve that
is often accompanied by other structural ocular abnormal-
ities. In addition, ONH is frequently associated with other
neurodevelopmental abnormalities, such as brain malfor-
mations, developmental delay, intellectual disability and
autism spectrum disorders.5–7 Genetically, variants in
genes involved in transcriptional regulation, chromatin
remodelling, scaffolding proteins and MAPK signalling
pathway have been associated with ONH. The transcrip-
tion factors implicated in ONH participate in the proper
development of the optic stalk (OS) and optic nerve by
directly participating in the intricate sequential steps coor-
dinating ocular morphogenesis and maturation.8
Bosch–Boonstra–Schaaf Optic Atrophy Syndrome
(BBSOAS) (OMIM 615722; ORPHA 401777) is an auto-
somal dominant disorder characterized by delayed neuro-
development, moderate to severe intellectual disability
and visual impairment.9 BBSOAS is caused by pathogenic
variants in the NR2F1 gene (OMIM 132890, 5q15),
which encodes a conserved orphan nuclear receptor pro-
tein acting as a strong transcriptional regulator. NR2F1
represents an evolutionarily highly conserved protein,10
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with a classic nuclear receptor structure and two highly
conserved domains: the functional DNA-binding domain
(DBD) and a ligand-binding domain (LBD). Structural
variants spanning NR2F1 were first reported as causing
human disease in patients with neurodevelopmental syn-
dromes characterized by mental retardation, epilepsy and
deafness.11,12 A subsequent functional study confirmed
the pathogenic nature of NR2F1 variants and their asso-
ciation with syndromic optic atrophy.9 Further cases have
since been reported that have expanded the phenotypes
associated with pathogenic variants in NR2F1 and high-
lighted the marked variability in disease severity.13–18
Visual impairment is one of the major features described
in BBSOAS with patients developing ocular, visual path-
way and cortical visual impairment in some cases.
However, the structural and functional defects within the
retina and the optic nerve need to be defined further to
provide greater insight into the pathophysiological mecha-
nisms of the disease, in particular, whether the defects
are congenital in origin and/or whether it is a progressive
neurodegenerative process occurring after birth.
A knockout Nr2f1 mouse model has recently been
characterized highlighting the importance of Nr2f1 in reg-
ulating the early development of the visual system,
including the formation of the optic cup and optic
nerve.19 We therefore capitalized on the availability of
such a mouse model to further delineate the post-natal
ocular expression pattern of Nr2f1 and to investigate the
deleterious consequences of Nr2f1 loss on retinal and
optic nerve development and maturation. To complement
these experiments, we also performed a detailed charac-
terization of NR2F1 in human foetal retina. In parallel,
we conducted a deep phenotyping study of 22 patients,
including familial cases, carrying a pathogenic NR2F1
variant with structural OCT imaging and electrophysio-
logical evaluation of visual function. The findings suggest
a neurodevelopmental basis for the observed visual im-
pairment associated with NR2F1 variants, rather than the
progressive RGC loss described in classical inherited optic
neuropathies. The use of a mutant Nr2f1 mouse model
to explore this hypothesis provided concordant observa-
tions, confirming that the loss of RGCs and axonal mis-
guidance in early development leads to ONH and the
development of optic atrophy, resulting in impaired visual
acuity, and with the severity of the structural defects de-
pending on the residual amount of wild-type protein.
Materials and methods
Study cohort
In this retrospective multicentre study, the clinical infor-
mation of individuals with confirmed pathogenic NR2F1
variants was reviewed to establish the phenotypic spec-
trum. The initial cohort of three NR2F1-positive families
was identified at Moorfields Eye Hospital NHS
Foundation Trust (London, UK), with the contribution of
additional families from Great Ormond Street Hospital
for Children NHS Foundation Trust (London, UK), the
Children’s Hospital of Philadelphia (Philadelphia, USA),
Gangnam Severance Hospital (Seoul, South Korea),
Hospital Sant Joan de Déu (Barcelona, Spain), University
Hospitals of Nı̂mes, Lille and Montpellier (France). The
recruitment centres interrogated their institutional clinical
databases for individuals with genetically confirmed
NR2F1 variants. Two of these individuals, NR2F1_10
(South Korea) and NR2F1_4 (France), have previously
been reported.18,20 This retrospective study adhered to
the tenets of the Declaration of Helsinki and the contri-
buting study centres had the relevant ethical and institu-
tional approvals.
Clinical phenotyping
All affected individuals underwent a comprehensive
neuro-ophthalmological examination during the initial
diagnostic workup or following the identification of a
pathogenic NR2F1 variant. When feasible, fundus imag-
ing and high-resolution spectral-domain Spectralis OCT
imaging (Heidelberg Engineering Inc., Heidelberg,
Germany) was performed. Segmentation was obtained
using the automated segmentation software for the
Spectralis OCT device (Heidelberg Engineering, software
version 1.9.10.0). Each macular OCT scan was inspected
to assess the accuracy of the automated segmentation in
the determination of retinal thickness. Manual adjust-
ments were made when needed. Retinal thickness maps
were overlapped with macula grid (1.0, 2.22, 3.45 mm
diameters) on OCT scans (Fig. 1A–C). The central 1 mm
diameter circle was defined as the central subfield, fol-
lowed by the inner 2.22 mm diameter ring and the outer
3.45 mm diameter ring. Both rings were divided into the
inner and outer superior, nasal, inferior and temporal
sectors, and average values were calculated per sector.
The built-in software was used to automatically calculate
separate thickness values for the retinal nerve fibre layer
(RNFL), retinal ganglion cell layer (GCL), inner plexi-
form layer (IPL), inner nuclear layer (INL), outer nuclear
layer (ONL), and retinal pigment epithelium (RPE) in the
inner and outer (global) circles, and for each sector. Eyes
with bad quality scans were excluded. The data obtained
were compared with age-matched healthy controls.
Macular normative data were generated from SD-OCT
images of 7 normal eyes from 5 individuals with no
known retinal or optic nerve disease, and best-corrected
visual acuity (BCVA) of 0.00 logMAR.
Electrophysiological investigation was available for
12 individuals, including pattern visual evoked potential
(PVEP, N¼ 9), flash VEP (FVEP, N¼ 11), pattern
electroretinography (PERG, N¼ 6) and full-field electrore-
tinography (ERG, N¼ 7), which were performed to
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incorporate the International Society for Clinical
Electrophysiology of Vision (ISCEV) standards.21–23
White matter tractography was performed on one subject
(NR2F1_10) to assess the functional connectivity of the vis-
ual pathway. Using the occipital pole and primary visual
cortex as a seed point, the inferior frontal–occipital fascic-
ulus, the superior longitudinal fasciculus, and the inferior
longitudinal fasciculus were reconstructed. High angular
resolution diffusion images were acquired using a spin-echo
EPI sequence with 3 multi-slice acceleration (TE 65 ms, TR
3200 ms, 64 directions, Bmax 3000, Bmin 0, 2 mm isotropic
voxel size). White matter fibre tracking and reconstruction
were performed using DSI Studio software (http://dsi-studio.
labsolver.org/ last accessed July 2021) with a sparse solution
of fibre orientation distribution function by diffuse
decomposition. Termination criteria were based on a thresh-
old of quantitative anisotropy of 1.7 and a conservative
angle change of >45˚.
Molecular genetic analysis
As part of the Genomic England 100 000 Genomes Project,
both pilot and main studies,24 individuals NR2F1_14
(GC22770, UK), NR2F1_16 (GC21441, UK), NR2F1_18
(GC23585, UK) and NR2F1_19 (GC23585, UK) from three
independent families diagnosed with inherited optic neur-
opathy were analysed by whole-genome sequencing. A multi-
step rare variant filtering pipeline was employed, as
previously described, to identify the most likely disease-caus-
ing variant.25 As autosomal dominant optic atrophy was
Figure 1 Optical coherence tomography (OCT) composite. (A) Schematic representation of method used to analyse SD-OCT scans
(normal eye). Macula grid of central (1.0 mm diameter), inner (2.22 mm diameter) and outer rings (3.45 mm diameter) was centred on the fovea.
The 9 sectors in the grid represent the areas where the thickness of the retinal layers (RNFL, GCL, IPL, INL, ONL and RPE) were measured.
Circular scan was used to evaluate parapapillary RNFL thickness. The arrow indicates the start position. (B) OCT profiles of two affected
individuals and normal control for comparison (single right eye selected). OCT B-scan of the peripapillary area showing preserved RNFL layer.
OCT B-scan through the macula showing thinning of the GCL. GCL thickness map indicates thinning of GCL in two affected individuals. (C)
Comparison of the thickness of four retinal layers within the inner and outer circles, and in nine sectors for individuals with NR2F1 variants
(pattern fill) and normal controls (grey) subjects. The grey scale indicates significant differences in retinal layer thickness between the NR2F1 and
control groups. The Mann–Whitney U-test was used to for statistical analysis. *P 0.05; **P 0.01; ***P 0.001; n.s., non-significant. GCL,
ganglion cell layer; II, inferior inner; INL, inner nuclear layer; IO, inferior outer; IPL, inner plexiform layer; NI, nasal inner; NO, nasal outer; ONL,
outer nuclear layer; RNFL, retinal nerve fibre layer; RPE, retinal pigment epithelium; SI, superior inner; SO, superior outer; TI, temporal inner;
TO, temporal outer.
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suspected (Fig. 2A), a minor allele frequency threshold of
<0.001 was used for all coding variants occurring in a virtual
panel of genes previously shown to be associated with inher-
ited optic neuropathies (https://panelapp.genomicsengland.
co.uk/panels/186/ last accessed July 2021). A similar analysis
was performed on whole-genome sequencing data from indi-
viduals in the Genomic England 100 000 Genomes Project to
identify additional individuals carrying pathogenic NR2F1
variants. The search was performed in October 2019.
Case NR2F1_2 (South Korea) was identified by whole-
exome sequencing using Twist Human Core Exome kit
(Twist Bioscience, San Francisco, CA, USA). A 429 targeted
genes panel sequencing was performed in NR2F1_3 (South
Korea) and NR2F1_10 (South Korea), with the
latter case having been previously reported.18 Cases
NR2F1_1 (Spain), NR2F1_13 (France) and NR2F1_21
(France) were identified by next-generation sequencing
(NGS). For NR2F1_1 (Spain), an NGS panel of 6710 genes
associated with pathologies described in the Human Gene
Mutation Database, GeneTest.org and the OMIM catalogue
was used for screening. In some cases, NextSeq500 Illumina
sequencing was performed a posteriori for validation of
NR2F1 variants identified by the NGS panel. Cases
NR2F1_13 (France) and NR2F1_21 (France) were identified
using an NGS panel of 88 nuclear genes known to cause
inherited optic neuropathies or disorders linked to disturbed
mitochondrial dynamics. Library preparation for each sam-
ple was carried out using SureSelect Target Enrichment
System for Sequencing on Ion Proton (Manuel number
G7530-90005). Sample emulsion PCR, emulsion breaking
and enrichment were performed using the Ion PITM Chip
Kit v2 BC (Cat. no. 4484270) and Ion PITM IC 200 Kit
(Cat. no. 4488377) and sequencing was undertaken using
sequencing with the Ion ProtonTM System. The cases from
the Children’s Hospital of Philadelphia (USA) were all iden-
tified by performing whole-exome sequencing, except
NR2F1_22 (USA) who underwent single-gene testing.
All the NR2F1 variants in the study cohort, and
their segregation if available, were confirmed by Sanger
sequencing. The Genome Aggregation Database (gnomAD,
https://gnomad.broadinstitute.org last accessed July 2021)
was used to assess for the rarity of the variants in the general
population. In silico analysis was performed to evaluate the
likely impact on protein function using Polymorphism
Phenotyping v2 (http://genetics.bwh.harvard.edu/pph2/ last
accessed July 2021) and Mutation Taster (http://www.muta
tiontaster.org/ last accessed July 2021) predictive algo-
rithms. The evolutionary conservation of the affected amino
acid residues across orthologues was assessed using Uniprot
sequence alignments (https://www.uniprot.org/help/se
quence-alignments last accessed July 2021).
Animal procedures
All mouse experiments were conducted in accordance
with the relevant national and international guidelines
and regulations (European Union rules; 2010/63/UE), and
with approval by the local ethical committee in France
(CIEPAL NCE/2019–548). Nr2f1 heterozygous (HET) and
homozygous (KO) mice were generated and genotyped as
previously described.26 Littermates of HET and KO mice
with normal Nr2f1 alleles were used as control wild-type
mice (WT). Midday of the day of the vaginal plug was
considered as embryonic day 0.5 (E0.5). Control and mu-
tant mice were bred in a 129S2/SvPas background. Both
male and female embryos and adults were used in this
study, with the age being specified for each specimen used
in specific experiments. Standard housing conditions were
approved by the local ethical committee in France
(CIEPAL NCE/2019–548). Briefly, adult mice were kept
on a 12-h light–dark cycle and three animals were housed
per cage with the recommended environmental enrichment
(wooden cubes, cotton pad and igloo), and with food and
water ad libidum. The protocols for immunofluorescence
(IF), in situ hybridization, Western blot, intracortical mur-
ine visual evoked potential (VEP) recording and three-
dimensional (3D) imaging of mouse tissues have been
provided in the Supplementary Appendix.
Collection and processing of human
samples
Cryostat section of non-pathological human foetuses was
kindly provided by Cécile Allet and Paolo Giacobini (Lille,
France; Agence de la Biomédecine, Saint-Denis la Plaine,
France, protocol n: PFS16-002), while GW24 and GW34
paraffin eye sections were provided by Fabien Guimiot
(INSERM U1141, Hôpital Robert Debré, Paris, France).
All experiments involving the use of human samples con-
formed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human
Services Belmont Report. Tissues were made available in
accordance with French bylaws (Good practice concerning
the conservation, transformation and transportation of
human tissue to be used therapeutically, published on 29
December 1998). For GW14 sections, a non-pathological
human foetus (14 gestational weeks, n¼ 1) was obtained
from a voluntarily terminated pregnancy after obtaining
written informed consent from the parents (Gynaecology
Department, Jeanne de Flandre Hospital, Lille, France).
The foetus was fixed by immersion in 4% PFA at 4C for
7 days. The tissues were then cryoprotected in 30%
sucrose/PBS for 3 days, embedded in Tissue-Tek OCT
compound (Sakura Finetek, USA), frozen in dry ice and
stored at 80C until sectioning. Frozen samples were cut
serially at 20mm using a Leica CM 3050S cryostat (Leica
Biosystems Nussloch GmbH, Germany).
Statistical analysis
All data were statistically analysed and graphically
represented using Microsoft Office Excel software (Version
2003), IBM SPSS Statistics Software (Version 26) and
GraphPad Prism (Version 7.00). Quantitative data are
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Figure 2 Genotype spectrum and optic nerve head imaging of study subjects. (A) Pedigrees of familial cases identified in our NR2F1
patient cohort. Red arrows indicate the probands of the two familial cases (GC 21441 and GC 23585). Black shading indicates affected
individuals. Grey shading denotes a history of poor vision in family members who have not been assessed formally. (B) Schematic representation
of the NR2F1 gene with three exons (black boxes) and the NR2F1 protein structure showing two domains (grey boxes). (C) Colour photographs
of the optic nerve heads demonstrating optic atrophy and/or optic nerve hypoplasia. Black arrows highlight the double-ring sign. OA—indicates
optic nerve heads with clinical signs of optic atrophy. The locations of the NR2F1 variants identified in our study cohort are indicated in red.
DBD, DNA binding domain; LBD, ligand binding domain.
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shown as the mean 6 SEM. For cell percentage/number
quantification after IF, measurements were performed on at
least 5 sections coming from 2 to 3 different animals, un-
less otherwise stated. Fixed embryos/eyes with damaged tis-
sues were excluded from any further analysis/processing.
Microscope images were processed with Photoshop or
ImageJ software, by randomly overlapping fixed-width
(100mm) rectangular boxes on the area of interest [e.g. sec-
tioned neural retina (NR)], then quantifying positive cells
inside the boxes. When calculating percentages over the
total cell number, the latter was quantified by counting
DAPIþ nuclei, unless otherwise specified. Data were ana-
lysed using the Mann–Whitney U-test or two-tailed
Student’s t-test (when comparing two data groups), or by
two-way analysis of variance (ANOVA) for comparison of
three or more groups. Statistical significance was set as
follows: *P 0.05; **P 0.01; ***P 0.001.
Data availability
The anonymized data that support the findings of this
study can be requested from the corresponding author.
Results
Pathogenic NR2F1 variants are
clustered within the DBD and LBD
A total of 19 NR2F1 variants were identified in the
study’s patient cohort, all of which are absent from the
gnomAD dataset (Table 1). Three variants, namely, c.290
A>C p.(His97Pro), rs1554074673; c.353 T>G
p.(Leu118*), rs1561523796; and c.1115T>C
p.(Leu372Pro), rs1554075105, were found in ClinVar
database. The majority of NR2F1 variants (13/19,
59.1%) are located within the DBD and LBD (Fig. 2B).
Nine (40.9%) individuals carried frameshift, stop-gain var-
iants or entire gene deletion, whereas 13 (59.1%) individ-
uals carried missense variants or small deletions/
duplications. The identified NR2F1 variants were pre-
dicted to be disease causing based on in silico analysis.
Multiple alignment of human NR2F1 orthologues con-
firmed the strictly conserved nature of the protein across
different species (Supplementary Fig. 1). In addition, we
report, for the first time, two familial NR2F1 cases. The
identified variants [c.1115T>C p.(Leu372Pro) and
c.1118_1123del p.(Arg373_Leu374del)] co-segregated with
disease status in other affected family members (Fig. 2A).
In the majority of families (14/19, 73.7%), the NR2F1
variants were found to be de novo or likely de novo.
Visual function in individuals
carrying pathogenic NR2F1 variants
Clinical data were available for 22 patients from 19 inde-
pendent families, with 20 patients not having been
reported previously. The mean age at the last ophthalmo-
logical assessment was 15.2 years (SEM ¼ 2.7 years,
range ¼ 1.5–49.0 years). There was an equal sex distribu-
tion with 11 women and 11 men. Vision impairment and
optic nerve head pathology were identified when individ-
uals were examined following referrals for nystagmus,
strabismus, poor fixation and/or concerns about neurode-
velopmental progress. Impairment of vision was noticed
in early childhood in all individuals, except for case
NR2F1_15 (UK), who was found to have subnormal vi-
sion in her 50 s (Table 2). However, that particular indi-
vidual had other classical features described in BBSOAS,
namely, delay in walking and speaking, and mildly dys-
morphic facial features. In addition to optic atrophy, all
affected individuals developed other neuro-ophthalmo-
logical and systemic deficits (Supplementary Table 1).
BCVA was available for 40 eyes from 20 individuals.
The mean LogMAR visual acuity at the last ophthalmo-
logical assessment was 0.64 (SEM ¼ 0.06, range ¼ 0–
1.70). Follow-up visual acuity data were available for 12
(63.2%) individuals (mean ¼ 8.9 years, range ¼
16 months—17.0 years) (Supplementary Table 2). Four of
these individuals were within the age group (up to 5 years
old) when visual maturation had not yet been reached.
Seven individuals (four with hyperopia, two with myopia
and one with emmetropia) retained stable vision since
their initial visit with each worsening being due to pro-
gression of an underlying refractive error, which was cor-
rected with the appropriate prescription. Only one
individual, NR2F1_16 (UK), experienced visual worsening
over an 11-year follow-up period with LogMAR visual
acuity decreasing from 0.43/0.30 at baseline to 1.48/1.48
at the last clinic visit (right eye/left eye). The latest refrac-
tion record indicated a change in refraction (patient be-
came myopic). The majority of the study cohort (20/22,
91.0%) had a refractive error with variable degrees of
hyperopia observed in 15/22 (68.2%) individuals (Table
2). The mean LogMAR BCVA was not significantly dif-
ferent between individuals carrying frameshift, stop-gain
variants or entire gene deletion (0.70, SEM ¼ 0.09, range
¼ 0–1.30) compared to those with missense variants or
small deletions/duplications (0.61, SEM ¼ 0.08, range ¼
0.10–1.70, P¼ 0.462). There was also no significant dif-
ference in mean LogMAR BCVA between patients with
variants located within the DBD (0.78, SEM ¼ 0.17,
range ¼ 0–1.70) and those with variants located within
the LBD (0.52, SEM ¼ 0.07, range ¼ 0.18–1.00,
P¼ 0.103).
Twelve individuals (54.5%) underwent visual electro-
physiological assessment. The original traces were avail-
able for five subjects tested at Moorfields Eye Hospital.
The diagnostic reports for the remaining subjects were
reviewed. The analysis of pattern reversal VEPs (PVEP)
was frequently complicated by the presence of nystagmus.
In two patients, there were better binocular than mon-
ocular responses in keeping with the increased nystagmus
under monocular viewing conditions. Monocular PVEPs
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were undetectable in four subjects. In three others with
available waveforms, responses were subnormal (<5 mV)
and characterized either by a single positive peak of ab-
normally short peak time (N¼ 1; peak time 80–82 ms); a
bifid waveform with abnormally early and late peaks
(N¼ 1); or a polyphasic waveform also lacking a clear
‘P100’ component (N¼ 1). Abnormal FVEPs were docu-
mented in 8/10 cases. For four of the five subjects in
whom the original recordings were available for review,
the FVEPs had a grossly abnormal waveform with a
prominent early positive peak (76–89 ms) followed by a
second broad positive component (170–220 ms). No sig-
nificant interocular asymmetry was present.
Pattern ERGs, being recorded binocularly, were less
susceptible to nystagmus than the PVEPs. P50 compo-
nents were of abnormally short peak time in three eyes
of two subjects (41–44 ms; lower limit of normal ¼
46 ms) including both eyes of a 21-year-old individual,
which showed additional reduction in the N95:P50 ratio
(1.0; lower limit of normal 1.1). Four eyes of three other
subjects showed asymmetry in the N95:P50 ratio, includ-
ing one subject who was tested using a large checker-
board field (right eye ratio ¼0.9; lower limit of normal
for a large stimulus field ¼ 1.0). Three eyes showed mild-
ly subnormal P50 components (minimum amplitude
1.7 mV; lower limit of normal ¼ 2.0 mV), associated with
a shortened P50 peak time in one. Full-field ERGs were
normal in all seven cases. Three subjects had follow-up
recording (intervals 1, 5 and 10 years) and none showed
definite clinically significant deterioration.
The effects of pathogenic NR2F1
variants on RGCs structure and
their projections
Fundus examination revealed variable optic atrophy in
17/22 (77.3%) individuals. Ten (45.5%) individuals had
small and/or tilted hypoplastic optic nerves. Colour optic
nerve head photographs were available for 12 (54.6%)
individuals (Fig. 2B). In 8 individuals, a yellowish peripa-
pillary halo, the so-called double-ring sign (Fig. 2B, black
arrows), was observed consistent with ONH. Proper
alignment and good quality OCT scans are difficult to
obtain in patients with nystagmus or behavioural disor-
ders. OCT imaging was available for 14 (63.6%) individ-
uals. High-resolution spectral-domain OCT macular scans
were available for further analysis in 7 eyes of 4 individ-
uals. Based on the peripapillary and macular OCT B-
scans visual inspection, the RNFL thickness was relatively
preserved in individuals carrying NR2F1 variants com-
pared with a more prominent thinning of the GCL (Fig.
1B). Macular OCT scans were used for further analysis.
The mean RNFL thickness was significantly thinner in
three segments, namely, the superior outer (P¼ 0.001),
inferior outer (P¼ 0.004) and nasal outer (P¼ 0.001) seg-
ments (Fig. 1C and Supplementary Table 3). The GCL
was significantly thinner compared with normal controls
in all except the temporal inner segment. A similar pat-
tern was observed for IPL layer thickness. In contrast,
the INL was significantly thicker in individuals carrying
NR2F1 variants compared with age-matched controls
(Fig. 1C). One individual, NR2F1_14 (UK), had serial
macular volume scans over a follow-up period of 5 years
(Supplementary Fig. 2). No marked change in RNFL and
GCL thickness was observed during that period.
Diffusion tensor imaging tractography studies were con-
ducted on individual NR2F1_10. Qualitative analysis of
the white matter tractography data showed a striking re-
duction and disorganization of all three major fasciculi
connected with the occipital lobe, namely, the inferior
longitudinal fasciculi, the superior longitudinal fasciculi
and the inferior frontal–occipital fasciculi (Fig. 3).
Pathogenic NR2F1 variants cause
significant neurodevelopmental
deficits
The majority of individuals (19/22, 86.4%) presented
with neurodevelopmental delay with speech and motor
delays being common manifestations. Seven (31.8%) indi-
viduals were diagnosed with autistic spectrum and/or at-
tention deficit hyperactivity disorders (Supplementary
Table 1). A review of the available neuroimaging studies
revealed abnormalities in 15 (79%) individuals with thin-
ning of the optic nerve, optic chiasm and corpus cal-
losum being frequent findings.
Dynamic expression of NR2F1 in
the developing human retina
Staining of NR2F1 on cross-sections of human foetal
eyes at gestational week (GW) 14 showed wide expres-
sion in the developing NR, with low to high levels
observed in most NR progenitor cells (mean ¼ 96.8%,
SEM ¼ 2.9%) and GCL (mean ¼ 93.9%, SEM ¼ 5.9%)
(Fig. 4A–E). RGCs in GCL were identified with the
established RGC marker Brn3a. There was also extensive
NR2F1 expression in the ciliary body and in the RPE,
with 99.3% (SEM ¼ 2.5%) of cells showing low-to-high
levels in the latter one (Fig. 4C–D00). RPE cells were read-
ily recognizable by their high melanin content on bright-
field microscopy (Fig. 4C00–D00). To investigate the
expression of NR2F1 in the human retina at a later de-
velopmental stage, GW24 eyes were sectioned and double
stained with the axonal fibre marker TUJ1, and with the
PAX6 marker for RGCs and amacrine cells to distinguish
the individual retinal layers (Fig. 4F–F0). Following
NR2F1 immunostaining in adjacent sections, abundant
signal was found in both the GCL and the INL, the lat-
ter being enriched with amacrine and bipolar cells, sug-
gesting that NR2F1 is expressed in the majority of these
three cell types (Fig. 4G–H). In comparison, 40.0% (SEM
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¼ 9.9%) of photoreceptor cells in the ONL showed
weak NR2F1 expression (Fig. 4H). By taking advantage
of the bipolar and Müller glia cell marker VSX2, 85.9%
(SEM ¼ 3.8%) of these cells were found to co-express
low-to-high levels of NR2F1 (Fig. 4I–J). As in GW14
samples, GW24 retinas showed high NR2F1 expression
in RPE cells (Fig. 4I0). NR2F1 continues to be highly
expressed in the GCL and INL at GW34, but it becomes
gradually downregulated in the ONL and RPE cells (Fig.
4K). In relation to the optic nerve and the optic nerve
head where S100bþ astrocytes are intermingled with
RGC fibres, 80% of S100bþ cells co-expressed low-to-
high levels of NR2F1 (Fig. 4L–P). These findings demon-
strate that NR2F1 is dynamically expressed in distinct
retinal cell types (notably RGC, bipolar and RPE cells)
during human retinal development.
Disrupted retinogenesis in Nr2f1
mutant mice result in non-
progressive RGC loss
The Nr2f1 mutant mouse line was used to further investi-
gate the role of NR2F1 in the development of the visual
system. The consequences of Nr2f1 haploinsufficiency in
heterozygous mutant mice (HET) or its complete loss in
homozygous knock-out mutant mice (KO or null) were
evaluated by comparing mutants with control wild-type
(WT) littermates. The presence of 50% of Nr2f1 pro-
tein levels in HET mutants or the complete absence of
Nr2f1 protein in KO embryos was demonstrated by
immunostaining in embryonic and post-natal tissue, as
well as quantified by Western blot (Supplementary
Fig. 3). In this study, we further evaluated RGC numbers
at later stages of retinogenesis by initially performing
immunostaining of WT and mutant retinas with the RGC
marker Brn3a at post-natal day 7 retinas (P7) (Fig.
5A–B00). Nr2f1 KO mice showed a significant loss of
RGCs (Fig. 5A–C), whereas the RGC density in mutant
HET mice revealed a non-significant reduction compared
with control WT littermates (Fig. 5C). Retinas from one-
month-old WT and HET animals were isolated to investi-
gate the abundance of retinal cell populations in fully
developed tissues. It was not possible to examine KO
animals as they do not survive past P8. Brn3a-positive
RGCs were significantly reduced in Nr2f1-deficient reti-
nas (Fig. 5D–F). Notably, immunostaining performed on
retinas from three-month-old HET animals showed a
similar RGC density, indicating that no further RGC loss
had occurred over time (Supplementary Fig. 4A–C).
Other retinal cell populations, namely amacrine and bipo-
lar cells, were also affected by Nr2f1-deficiency (Fig. 5G–
L). There was a significant increase in Calbindin-positive
amacrine cells located in mutant eyes compared with con-
trols (Fig. 5G–I). Owing to a small expression overlap
between Calbindin and Brn3a in the GCL (13.2% double
positive cells; Supplementary Fig. 4D and E), only ama-
crine cells in the INL were included in the analysis.
Vsx2-expressing bipolar and Müller glia cells were signifi-
cantly reduced in HET mice (Fig. 5J–L), whereas the
average density of photoreceptors (PRs) at one month of
age was unchanged (Supplementary Fig. 4F), consistent
with low expression levels of Nr2f1 in the ONL
(Fig. 4H, K). Whole-mount retinal explants from one-
and five-month-old animals were processed to evaluate
Figure 3 White matter tractography with high angular resolution diffusion imaging (HARDI). (A) Healthy control subject with
normal vision. (B) Individual NR2F1_10 harbouring the c.513C>G p.(Tyr171*) variant. White matter tractography shows a marked reduction of
fibres within all three major fasciculi: inferior longitudinal fasciculi (ILF), superior longitudinal fasciculi (SLF) and inferior frontal-occipital fasciculi
(IFOF). The colour scheme corresponds to the fibre orientation plane (green: anterior to posterior; red: left to right; blue: head to feet).
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Figure 4 NR2F1 expression during human retinal development. (A–E) BRN3A (green; RGCs) and NR2F1 (red) immunofluorescence
(IF) on a sagittal section of a human GW14 eye, showing NR2F1 expression in almost all NR progenitors and retinal ganglion cells (NPs and
RGCs; B–B00), and in virtually all retinal pigmented epithelial cells (RPE; C–D00). The RPE (black) and the ciliary body (CB) are visible in merged
fluorescent/brightfield (empty and full arrowheads, respectively, in C–D00). The percentage of NR2F1-expressing NPs, ganglion cell layer (GCL)
cells or RPE cells is shown in graph (E). n 4/5 retinal regions from n¼ 1 eye (GW14 human embryo). (F–H) PAX6 (green in F, F0), NR2F1 (red
in G, G0) or TUJ1 (red in F, F0) IF on GW24 NR cross-sections. Ganglion cell, inner nuclear and outer nuclear layers (GCL, INL and ONL,
respectively) and retinal nerve fibre, inner plexiform and outer plexiform layers (rnfl, ipl and opl, respectively) were identified based on the
position of DAPIþ nuclei and double staining of TUJ1/PAX6 (F, F0), which allowed the quantification of NR2F1 levels in different retinal layers (H).
n¼ 4 retinal regions from n¼ 2 eyes (GW24 human retina). Arrowheads in (G, G0) point to cells in the GCL showing high NR2F1 level. (I–K) IF
with VSX2 for bipolar cells or Müller glia cells (green in I) and NR2F1 (red in I, I0) on GW24 human NR. Arrowheads in (I–I00) point to RPE cells
expressing high NR2F1. The proportion of VSX2þ cells or RPE cells expressing no, low or high NR2F1 is shown in graph (J). n¼ 4 retinal
regions from n¼ 2 eyes (GW24 human retina). (K) Histogram showing the percentage of cells in GCL, INL, ONL and RPE expressing either low
or high NR2F1 levels in GW34 human retina. n¼ 10 retinal regions from n¼ 3/4 eyes (n¼ 2 GW34 human embryos). (L–P) IF with S100b for
astrocytes (green in M, N, O) and NR2F1 (red in M–O0) on a sagittal section of a human GW34 eye showing the optic nerve head (ONH;
magnification in N, N0) and a portion of the optic nerve closest to the NR (magnification in O, O0). The proportion of ONH or optic nerve
astrocytes expressing no, low or high levels of NR2F1 is shown in graph (P). n¼ 10 ONH/ON regions from n¼ 3/4 eyes (n¼ 2 GW34 human
embryos). Nuclei (blue) were stained with DAPI. The data have been represented as mean 6 SEM in the graphs. Scale bars: 50 mm, except A, L,
M (100 mm). BPs, bipolar cells; CB, ciliary body; CMZ, ciliary marginal zone; GCL, ganglion cell layer; GW, gestational week; INL, inner nuclear
layer; ipl, inner plexiform layer; NPs, neural progenitors; NR, neural retina; ON, optic nerve; ONH, optic nerve head; ONL, outer nuclear layer;
opl, outer plexiform layer; RGCs, retinal ganglion cells; rnfl, retinal nerve fibre layer; RPE, retinal pigmented epithelium.
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Brn3a-positive RGC numbers and their distribution with
higher spatial resolution (Supplementary Fig. 4G–N and
Fig. 5M–T). The RGC density in HET mutants (63.7
Brn3aþ cells per 10.0 mm2, SEM ¼ 2.6) was reduced in
the proximal (central-most) retina compared with control
animals (69.3 Brn3aþ cells per 10.0 mm2, SEM ¼ 1.9,
P¼ 0.044) (Fig. 5N–P). In the distal (peripheral) retina,
HET mutants showed a more prominent reduction in
RGC density (44.8 Brn3aþ cells per 10.0 mm2, SEM ¼
1.9) than control animals (56.3 Brn3aþ cells per 10.0
mm2, SEM ¼ 2.4, P< 0.001) (Fig. 5Q–S). A comparable
decrease in RGC density was observed in retinas from
one- and five-month-old HET mutants, confirming the
non-progressive nature of the RGC loss (Fig. 5T). The
Figure 5 Altered retinal development secondary to Nr2f1 loss in a mouse model. (A–C) Brn3a (green; RGCs) immunofluorescence
(IF) at post-natal (P) day 7 of retina from wild-type (WT; A–A00) and Nr2f1 knock-out mutant (KO; B–B00) mice. Partial (heterozygous; HET) or
complete (KO) Nr2f1 loss leads to a reduction in Brn3aþ RGC count (C) [WT/HET: non-significant (n.s.) ¼ 0.1135; WT/KO: * ¼ 0.0325]. (D–F)
Brn3a (green; RGCs) and Nr2f1 (red) IF on retina from one-month-old (1 m) WT (D–D00) and mutant HET (E–E00) mice. The arrowheads in
(D0–E00) point to double Nr2f1þBrn3aþ RGCs. The retinal density of RGCs is quantified in (F) (WT/HET: * ¼ 0.0195). For a similar quantification
performed on 3-months-old retinas, see Supplementary Fig. 4C. (G–I) IF with Calbindin (green) for amacrine and horizontal cells, and Nr2f1
(red) in retina from 1 m-old WT (G–G0 00) and mutant HET (H–H0 00) mice. The relative density of Calbindinþ cells (ACs) in the INL is shown in (I)
(WT/HET: ** ¼ 0.0053). (J–L) IF with Vsx2 (green) for bipolar and Müller glia cells and Nr2f1 (red) in retina from 1 m-old WT (J–J0 00) and mutant
HET (K–K0 00) mice. The density of Vsx2þ cells in INL is shown in (L) (WT/HET: *¼0.0187). (M–T) Whole mount IF with Brn3a (green) for RGCs
and Nr2f1 (red) in retina from 5-month-old (5 m) WT (M, N and Q–Q0 00) and mutant HET (O, R) mice. Yellow arrowheads in (Q0–Q0 00) point to
double Brn3þNr2f1þ RGC cells, while red arrowheads highlight Brn3-Nr2f1þ (probably amacrine) cells. The density of Brn3aþ RGCs in proximal
or distal retinal regions is shown in (P) and (S), respectively, while quantification on the whole retinal surface is shown in Supplementary Fig. 4N
(WT proximal/HET proximal: * ¼ 0.05; WT distal/HET distal: ** ¼ 0.0023). For a similar quantification performed on 1 m-old whole mount
retinas, see Supplementary Fig. 4G–M. The percentages of RGC density reduction (ratio between HETRGC density and WTRGC density) in 1 m or
5 m-old retinas and quantified in different regional regions (total, proximal and distal) are shown in Graph (T); a similar trend was found at 1 m
and 5 m, suggesting relatively stable RGC reduction during mouse adult lifespan. In graphs (C, F, I, L), the number of positive cells was quantified
in 60 mm-width boxes, randomly placed across the NR. In graphs (P, S), the number of Brn3aþ cells was counted within squares of 100 mm-width
regions, randomly placed in the central (proximal) or peripheral (distal) regions of flattened whole-mount retinal explants; Brn3aþ cell number
was normalized on the average RGC density in 5 m WT retinas (shown in Supplementary Fig. 4M). n 4/6 eyes from 2/3 animals per genotype,
except P and S (n¼ 4 retinas from n¼ 2 animals per genotype). The nuclei (blue) were stained with DAPI. The data have been represented as
mean 6 SEM. The student’s t-test (F, I, L, P and S) and one-way ANOVA (C) were used for statistical analysis (*P< 0.05; **P< 0.01;
***P< 0.001). Scale bars: 50 mm, except A, M (100 mm). 1 m, 1 month-old; 3 m, 3 months-old; A.U., arbitrary unit; AC, amacrine cell; BP, bipolar
cell; GCL, ganglion cell layer; INL, inner nuclear layer; NR, neural retina; ONL, outer nuclear layer; RGC, retinal ganglion cell.
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reduction of RGCs caused by the absence of Nr2f1 can,
therefore, be detected from the early post-natal stages
without further loss occurring from one month of age
onwards. These observations indicate that Nr2f1 is key
factor for establishing correct retinogenesis during
development.
Abnormal optic nerve development
and RGC axonal guidance in Nr2f1
mutant mice
Given the prominent optic nerve head abnormalities
described in individuals carrying NR2F1 variants, optic
nerve development was investigated in HET and KO mu-
tant mice. The presumptive optic disc region, located be-
tween the NR and the OS, displayed an abnormally
decreased number of Pax2-positive cells in Nr2f1 mutants
during early eye development (Fig. 6A and B). Netrin1
expression was tested as it is known to locally guide
RGC axons in the optic disc region. In keeping with an
aberrant patterning at the NR/OS border, Netrin1 was
abnormally distributed in HET and KO E12.5 optic
vesicles (Fig. 6C and D). Notably, Netrin1 expression
was lost in the dorsal OS of KO embryos (empty arrow-
head in Fig. 6D), but it was maintained in the ventral
OS (blue arrowheads in Fig. 6D). The early neuronal
marker Tuj1 highlighted how developing RGC axons
tended to be positioned ventrally in KO mice, presum-
ably guided by the higher Netrin1 ventral expression, as
illustrated in transverse sections of the optic nerve (Fig.
6E and F). RGC fibres that normally fill the OS in its
dorsal-most area were reduced by 48.8% (SEM ¼
14.8%) in HET and by 75.3% (SEM ¼ 14.0%) in KO
animals compared to control WT littermates (Fig. 6F).
This misguidance defect was still evident at later stages
(E15.5; Fig. 6G, G0, J).
Tuj1 immunostaining on clarified whole embryonic
heads, followed by light-sheet imaging and 3D recon-
struction, was used to visualize the RGC axonal pathway
in its entirety (Fig. 6H and Supplementary Fig. 5A). At
E13.5, 3D views of the retina confirmed anatomical mal-
formations in the ventral retina and in the optic nerve
head regions of mutant animals (Fig. 6I–I00 and
Supplementary Fig. 5B–C0). Moreover, Tuj1þ fibre mis-
guidance was readily apparent in the 3D reconstructions
(Fig. 6I–I00). Virtual transverse sectioning at different lev-
els showed that the morphological defects in mutant mice
spanned the whole length of the developing optic nerve
(Fig. 6I00), with RGC axons failing to fill the dorsal-most
half of the optic nerve as observed in WT mice (Fig.
6I–I00 and Fig. 6J). Taken together, these early develop-
mental defects emphasize the major deleterious conse-
quences of Nr2f1 loss on the final morphology and fibre
organization within the developing optic nerve, in par-
ticular the optic nerve head. A more severe defect was
also observed in KO mice compared with HET mice
(Fig. 6J).
Decreased visual acuity in Nr2f1
haploinsufficient mice
To investigate whether the retinal and optic nerve defects
result in functional visual impairment in the Nr2f1 mu-
tant mouse model, VEPs were recorded from the binocu-
lar portion of the primary visual cortex of three-month-
old WT and Nr2f1 haploinsufficient mice. Recordings
were performed with silicon probes spanning all the cor-
tical layers in awake, head-restrained animals
(Supplementary Fig. 6A). The VEP recording has two
main components, an early negative wave (N1) and a
late positive peak (P1) (Supplementary Fig. 6B). The peak
time of both components was significantly increased in
HET compared with WT mice (Supplementary Fig. 6C
and D). VEP amplitude was also significantly decreased
in layers II–III of mutant animals (Supplementary Fig. 6E,
G–I). The spatial resolution, which is a surrogate param-
eter of visual acuity, was calculated by presenting
gratings of increasing spatial frequency and it was signifi-
cantly reduced in HET mice (Supplementary Fig. 6F).
Together, these data confirm impaired visual function in
Nr2f1 mutant mice, similar to what is observed in
patients carrying NR2F1 variants.
Discussion
This study demonstrates that the optic neuropathy caused
by pathogenic NR2F1 variants is of early neurodevelop-
mental origin, with limited evidence of progression in
later life. This is in contrast with other inherited optic
neuropathies caused by pathogenic gene variants in nu-
clear DNA, which are typically associated with progres-
sive visual loss from early childhood.27 In the current
patient cohort, 22 individuals with pathogenic variants in
NR2F1 were investigated, including familial cases.
Despite the high prevalence of visual system deficits in
previously reported individuals with NR2F1 variants,9,14–
18,28 there are limited data on the ocular phenotype and
the disease mechanisms that contribute to visual loss in
affected individuals, since previous reports mainly
focussed on the systemic clinical features.19,29
Furthermore, the developmental pattern and timing of
NR2F1 expression in different human retinal cell types
have not been assessed.
A detailed ophthalmological characterization of the
NR2F1 patient cohort points towards the visual loss in
affected individuals being congenital in origin, with
marked loss of neural cells within the inner retinal layers
of the macula, and non-progressive in later life. Visual
impairment was apparent in early childhood with nystag-
mus, fixation problems, strabismus and relatively pre-
served visual acuity compared to the structural changes
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Figure 6 Altered optic nerve head development and Netrin1-dependent RGC axon guidance secondary to Nr2f1 loss. (A–B) Pax2 (red;
presumptive ONH astrocytes at the NR/OS border) and Tuj1 (green; RGC axons) immunofluorescence (IF) of eye cross-sections from wild-type
(WT; A), heterozygous (HET; A0) and knock-out mutant (KO; A00 and B) mice at embryonic day (E) 12.5. Partial (HET) or complete (KO) Nr2f1 loss
results in decreased number of Pax2þ cells located in the developing optic disc region (delineated area and white arrowheads in A–B). Red
arrowheads in (B) indicate the ventral optic stalk (vOS) regions maintaining Pax2 expression. (C–D) In situ hybridization of Netrin1 mRNA in eye
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within the retina. The youngest individual was diagnosed
at the age of 3 months old and there was no evidence of
progression in those with follow-up data, which ranged
from 9 months to 17 years. Of note, a proportion of indi-
viduals were diagnosed with ONH in addition to OA,
and hyperopia was the predominant refractive error. As
hyperopia can be amblyogenic, early effective intervention
to correct the underlying refractive error should be con-
sidered to prevent secondary vision deterioration.
The description of ONH may sometimes be confused
with OA and their co-occurrence can lead to diagnostic
challenges.30 ONH is associated with poor fixation, ab-
normal eye movements, nystagmus, strabismus, hyper-
opia,31 and vision ranging from no light perception to
good functional vision,32,33 similar to the findings in this
study. Moreover, ONH is often syndromic in nature
occurring in conjunction with structural malformations of
the brain.7 The most common neuroanatomical malfor-
mation found in patients with ONH is hypoplasia of the
corpus callosum associated with developmental delay,
neurological deficits and seizures,6,34 which are all clinical
features observed in children carrying disease-causing
NR2F1 variants.16,19 In addition, ONH is characterized
by congenital deficiency of RGCs and their axons, which
lead to disorganization of the GCL, RNFL thinning, and
a small optic disc with a thin optic nerve. Various theo-
ries have been proposed to explain the aetiology of
ONH, including a developmental failure of RGCs.35–38
Available monocular pattern reversal VEPs were all se-
verely abnormal. A better formed or detectable binocular
response suggested that the manifest/latent nystagmus was
contributory to the poor monocular responses in a mi-
nority of patients. The normal or near-normal PERG P50
components (recorded binocularly and thus less suscep-
tible to latent nystagmus) indicate preserved macular
function, and the markedly abnormal PVEPs are thus not
a consequence of macular disease. The PERG abnormal-
ities included a shortened P50 peak time and reduction in
the N95:P50 ratio, consistent with RGC dysfunction.
Shortening of P50 peak time, possibly with some P50
component involvement, has been demonstrated clinically
in various disorders including demyelination, inherited
optic neuropathies and optic nerve compression,39,40 but
also occurs following tetrodotoxin blocking of spiking
cell function in a non-human primate.41 The P50 compo-
nent is not abolished simply by loss of RGC function.
Flash VEPs (mostly unaffected by nystagmus) were gross-
ly abnormal in the majority of patients, with waveform
distortions and a lack of the typical major positive com-
ponents. There was no evidence from the normal ERGs
obtained in the limited subgroup of patients in whom
ERG was performed of any retinal dysfunction, and the
abnormal flash VEPs therefore reflect post-retinal dys-
function. ERGs included assessment of the oscillatory
potentials, thought to arise largely in response to activity
of the amacrine cells. There was no association between
the severity of VEP abnormalities and age, broadly in
keeping with stable visual pathway dysfunction and the
clinical data. Some patients may show slight improvement
in the electrophysiological data over time, but this may
simply relate to lessening of the nystagmus or improved
compliance.
Both axonal damage with RNFL thinning and neuronal
cell body degeneration with GCL thinning were quanti-
fied in affected individuals carrying pathogenic NR2F1
variants by high-resolution OCT imaging. The RNFL,
GCL and IPL layers, which contribute to the ganglion
cell complex, were significantly thinner in the patient
group compared with age-matched healthy controls. The
thinning of the RNFL layer was segmental in nature
compared with other inherited optic neuropathies, such
as OPA1-related and WFS1-related dominant optic
Figure 6 Continued
cross-sections from E12.5 WT (C), HET (C0) and KO mutant (C00 and D) embryos. A higher magnification picture of the ONH region of a KO
embryo is shown in (D). The dorsal optic stalk (dOS) fails to express Netrin1 (empty arrowheads in C00 and D), whereas the vOS regions show
abundant Netrin1 expression (blue arrowheads in D). (E–F) Tuj1 IF showing RGC axonal fibres (green) on OS cross-sections of control WT (E),
HET (E0) and KO mutant (E00) embryos at E13.5. Most axonal fibres follow a ventral path in KO OS, probably due to the absence of attractive
guidance signals, such as Netrin1, in the dorsal-most ONH region. The average surface occupied by Tuj1þ RGC axons in dorsal OS regions is
quantified in (F) (WT/HET: ** ¼ <0.0013; WT/KO: *** ¼ <0.0001; HET/KO: ** ¼ 0.0037; n 4/5 optic stalks from n¼ 3 embryos per genotype).
(G–G0) IF with Tuj1 of RGC axonal fibres (green) on OS cross-sections of control WT (G) and KO mutant (G0) embryos at E15.5, showing
persisting decrease of axonal fibres in the dorsal OS of mutant animals. (H) Three-dimensional (3D) imaging of an E13.5 HETembryo head after
Tuj1 IF and tissue clearing. A false green colour has been used to highlight the retina and the ON. (I–I00) 3D reconstruction of Tuj1þ axonal fibres
exiting the retina (dark green) and entering the OS (light green) in WT (I), HET (I0) and KO (I00) E13.5 embryos. Dotted lines in (I) show the levels
of transverse sections (1–4) displayed in the panels on the right. The white arrowheads point to ONH malformation in KO embryos, whereas the
red arrowheads highlight reduced Tuj1 staining in the dorsal aspect of the developing ON in both mutant HETand KO embryos. (J) Schematic
representation of the developing OS (blue) and NR (grey) in WT, HETand KO mouse eyes. As dorsal optic disc cells lose Netrin1 expression in KO
mutants (arrowhead), RGC axons (green) are attracted towards the ventral region of the developing ONH, where some Netrin1 signal is still
present; furthermore, RGC axons in mutants fail to invade the dorsal-most half of the developing ON. The nuclei (blue) were stained with DAPI.
The data have been represented as mean 6 SEM. The one-way ANOVA test was used for statistical analysis (**P< 0.01; ***P< 0.001). Scale
bars: 50 mm, except H (300mm) and G–G00 (100mm). dOS, dorsal optic stalk; NR, neural retina; ONH, optic nerve head; OS, optic stalk; RGC,
retinal ganglion cell; vOS, ventral optic stalk.
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atrophy, in which more generalized RNFL thinning has
been reported in all segments.42–44 It is well established
that the ganglion cell complex becomes thinner in dis-
eases affecting RGCs, including inherited optic neuropa-
thies.45,46 The INL, consisting of the dendrites of RGCs,
bipolar, amacrine and Müller glial cells, was significantly
thicker in our NR2F1 cohort compared with age-matched
controls. Thickening of the INL has been observed in
advanced glaucoma cases and a possible explanation are
Müller glial cells undergoing morphological changes and
hypertrophy in response to the underlying insult.47–49
Diffusion tensor imaging tractography imaging was avail-
able for one individual, NR2F1_10, and it is possible
that defective connections of the extracortical visual path-
ways are contributing to visual-oriented neurodevelop-
mental problems such as impaired object recognition
performance.50
Consistent with the ocular features described in
BBSOAS, NR2F1 is highly expressed in the human eye,
following cell differentiation from mitotic retinal progeni-
tors to post-mitotic RGCs, as previously suggested.19 The
genomic sequence and function of NR2F1 have been
highly conserved in evolution, providing the opportunity
to use mouse models to investigate the role of this gene
in brain pathologies.10,19 It was recently demonstrated
that Nr2f1-deficient mice recapitulate some of the key
deficits observed in affected individuals, in particular, the
ocular defects,19 and neocortical malformations.20 The
Nr2f1 mutant mouse model was therefore used to pro-
vide further insights into the relevance of NR2F1 to ret-
inal and optic nerve development at later post-natal
stages and during adulthood. HET mice replicate the
human form of the disease, in which one allele has been
lost resulting in decreased NR2F1 protein production.19,51
Several features of abnormal visual system development,
such as ONH, early differentiation of RGCs at embryon-
ic and early post-natal stages and cerebral visual impair-
ment, could be faithfully recapitulated and investigated
using this well-characterized mouse model.19 As RGCs
elongate their axons to form the optic nerve, the reduced
RGC density with thinning of the GCL offers an obvious
explanation for the development of ONH in this mouse
model (this study and reported by Bertacchi et al.19).
Other retinal cell populations, in particular, Calbindin-
expressing amacrine and Vsx2-expressing bipolar and
Müller glia cells, are also affected by Nr2f1 haploinsuffi-
ciency, suggesting that RGC layer imbalance secondary to
Nr2f1 loss could have deleterious consequences for the
retinal circuitry as a whole.52 However, the marked loss
of RGCs remains the primary characteristic of Nr2f1
haploinsufficient mice, detectable during early post-natal
development and confirmed in one-, three- and five-
month-old retinas with no progressive degeneration. This
matches the findings in our NR2F1 patient cohort with
OCT imaging showing RGC layer thinning and visual
electrophysiology confirming RGC dysfunction. Of note,
RGC density remained stable in post-natal and adult
Nr2f1 mutant mice. Given that affected individuals in the
NR2F1 patient cohort retained relatively stable visual
acuities during an extended period of follow-up, the over-
all evidence points towards a non-progressive process
mainly due to a failure of RGC production in early em-
bryonic development, rather than a more gradual loss of
RGCs over time. This explanation would also account
for the high prevalence of ONH in this patient
population.
Nr2f1 has been proposed to orchestrate the expression
of key molecular determinants, such as Pax6 and Pax2,
in the NR and OS, including the border regions corre-
sponding to the developing optic nerve head.19,53 This
structure constitutes a critical region for eye function
with secreted molecules, such as Netrin1, locally guiding
RGC axons as they exit the retina and promoting their
survival during neuronal navigation.54–56 Indeed, lack or
reduced Netrin1 expression prevents the organized topo-
graphical migration of RGC axons from the NR into the
OS, causing optic disc abnormalities if the dysfunction is
severe enough.54,55 In this study, we define an important
pathological mechanism arising from the loss of Nr2f1.
Strikingly, the optic disc lacks a properly defined key mo-
lecular signature (Netrin1) that normally guides RGC
axons from the inner retina towards the OS, resulting in
misrouting of RGC fibres. By employing novel tissue
clarification protocols,57,58 we were able to generate a
detailed structural map of the axonal fibres exiting the
NR and entering the optic disc. The morphological
defects spanned the whole length of the OS and as one
would expect from the complete loss of Nr2f1, the failure
of proper RGC axonal navigation was more pronounced
in KO mice. Previous studies in mice have demonstrated
a role for Nr2f1 in regulating axonal elongation and
guidance in different brain regions.26 The present data
suggest a similar role in the visual system, both at the
level of the retina by orchestrating Netrin1 expression
and RGC differentiation, and at the central brain tract
level, as demonstrated by white matter tractography
imaging. Altogether, the data indicate that loss of Nr2f1
expression affects the organization of the optic nerve
head region, further reinforcing the notion that visual
loss in individuals carrying pathogenic NR2F1 variants
arise from pathological events in early development.
Furthermore, given the highly conserved evolutionary role
of NR2F1,29 we hypothesize that the molecular domain
shift at the optic nerve head border could account for the
ONH described in a proportion of affected individuals.
Finally, electrophysiological recordings were used to
evaluate visual system spatial resolution, a surrogate of
visual acuity, in Nr2f1 mutant mice. Nr2f1 haploinsuffi-
ciency led to delayed signal transmission and reduced
VEP amplitude, in keeping with the observed optic nerve
abnormalities and the retinal alterations in bipolar and
RGC cell populations. Spatial resolution (acuity) was also
significantly decreased. The Nr2f1 HET mouse may,
therefore, represent an efficient system to recapitulate the
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vision loss in BBSOAS and, more generally, an attractive
genetic model to further study retinogenesis and the
mechanisms driving RGC loss in early development.
In conclusion, this study provides a comprehensive de-
scription of the ophthalmological phenotypes in a cohort
of individuals carrying pathogenic NR2F1 variants, pro-
viding new insights into the underlying structural ocular
defects and functional consequences on vision. The find-
ings from the Nr2f1 mouse model indicate that the ret-
inal and optic nerve head anomalies associated with
Nr2f1 deficiency represent a primary RGC patterning
and axonal guidance defect originating during early de-
velopment. These observations are particularly relevant
given that half of all patients carrying pathogenic NR2F1
variants develop ONH as a prominent ocular feature.
Furthermore, the longitudinal visual data collected in our
NR2F1 patient cohort indicate that the visual loss arises
due to an insult occurring early in development with no
evidence of marked progression later in life. A prospect-
ive study involving a larger cohort of patients assessed
using a standardized protocol and spanning a longer fol-
low-up period is needed to confirm that visual loss is
non-progressive in BBSOAS, which has important impli-
cations for genetic counselling and patient management.
Supplementary material
Supplementary material is available at Brain
Communications online.
The authors would like to thank Dr Cara M. Skraban
(Roberts Individualized Medical Genetics Center,
Children’s Hospital of Philadelphia, Philadelphia, PA,
USA) for assistance with clinical characterization and gen-
etic testing. We are also grateful to Dr Fabien Guimiot
from the Inserm U1141 Unit at the Robert Debré
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